Showing 1 posts of 1 posts found.
Celgene has had a rough six months, its share price since the beginning of October has dropped from $146 to …
From lab breakthrough to NHS treatment: Getting innovative therapies to patients
Five Facts about NHS and primary care
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
AI in pharma: From lab development to patient impact
Back to basics: X-ray inspection in pharmaceutical and medical device production